Editorial

On January 1, 2006, I appointed 33 eminent

scientists to 3-year terms on the

Journal of

Pharmaceutical Sciences (JPharmSci) Editorial
Advisory Board (EAB). The terms of these
individuals will expire on December 31, 2008. I
am pleased to announce here that the following
individuals have accepted reappointments to the
JPharmSci EAB for another 3-year term (January
1, 2009–December 31, 2011): David Brems,
Amgen, Inc.; Annette L. Bunge, Colorado School
of Mines; Henry R. Costantino, Costantino Con-
sulting; John H. Crowe, University of California,
Davis; Richard T. Darrington, Boehringer-Ingel-
heim Pharmaceuticals, Inc.; Elias Fattal, Uni-
versity of Paris-Sud; Barrie C. Finnin, Monash
University; Igor Gonda, Aradigm Corporation;
Jonathan Hadgraft, University of London; James
N. Herron, University of Utah; Munir A. Hussain,
Bristol-Myers Squibb Company; Lisbeth Illum,
Identity; Gregory T. Knipp, Purdue University;
William J. Lambert, Pacira Pharmaceuticals, Inc.;
David Lechuga-Ballesteros, Aridis Pharmaceuti-
cals; Patrick J. McNamara, University of Ken-
tucky; Marilyn E. Morris, University at Buffalo;
Eric Munson, University of Kansas; John S.
Patton, Pikamab; Ve´ronique Pre´at, Universite´
Catholique de Louvain; Thomas J. Raub, Eli Lilly
& Company; Christian Scho¨neich, University of
Kansas; Richard L. Schowen, University of
Kansas; Ravi M. Shanker, Pfizer Global R&D;
Ronald A. Siegel, University of Minnesota; Raj
Suryanarayanan, University of Minnesota; Lynne
S. Taylor, Purdue University; Jashvant D. Unad-
kat, University of Washington; Michel Vert,
CNRS-University Montpellier 1; Timothy Wied-
mann, University of Minnesota; Akira Yamamoto,
Kyoto Pharmaceutical University; Hiroaki Yuasa,
Nagoya City University; and Cheryl L. Zimmer-
man, University of Minnesota.

I would like to publicly thank the following

individuals who have served on the

JPharmSci.

EAB for the past 3 years: Sandra Allerheiligen, Eli

Lilly & Company; William Elmquist, University of
Minnesota;

Pam

Golden,

GlaxoSmithKline;

Robert Hider, King’s College London; Christopher
Lipinski, Pfizer; Kenneth Morris, University of
Hawaii; Emi Nakashima, Kyoritsu University;
Jeffrey

Silverman,

Sunesis

Pharmaceuticals,

Inc.;

Yuichi

Sugiyama,

The

University

of

Tokyo; Hiroshi Suzuki, University of Tokyo
Hospital; Peter Swaan, University of Maryland;
Jim

Wright,

Infinity

Pharmaceuticals;

and

Sumie Yoshioka, National Institute of Health
Sciences.

I am also pleased to announce here the

appointment of the following new EAB members
to 3-year terms starting on January 1, 2009: Cory
Berkland, The University of Kansas; Giampiero
Bettinetti, University of Pavia; Steven Bishop,
MedImmune; Mino R. Caira, University of Cape
Town; William N. Charman, Monash University;
Richard H. Guy, University of Bath; Bruno C.
Hancock, Pfizer Inc.; Ichiro Ieiri, Kyushu Uni-
versity; Devendra S. Kalonia, University of
Connecticut; Yukio Kato, Kanazawa University;
Bruce A. Kerwin, Amgen; MNV Ravi Kumar,
University of Strathclyde; Hiroyuki Kusuhara,
The University of Tokyo; Hanns-Christian Mah-
ler, F. Hoffmann-La Roche Ltd.; Cynthia A.
Maryanoff, Cordis Corporation; Yvonne Perrie,
Aston University; David Putnam, Cornell Uni-
versity; Chang-Koo Shim, Seoul National Uni-
versity; Mikihisa Takano, Hiroshima University;
Yasuo Tsutsumi, Osaka University; Guy Van den
Mooter, Catholic University of Leuven; Kouichi
Yoshinari, Tohoku University.

With these reappointments and new appoint-

ments to the EAB, this advisory group remains at
a steady-state level of approximately 150 mem-
bers. The Associate Editors and I feel that the
composition of the EAB appropriately reflects the
diversity

of

scientific

disciplines

served

by

JPharmSci and the diversity of its international
audience. In addition, we feel that the EAB is
sufficiently large to ensure that an adequate
number of experts are available to conduct timely
reviews of the approximately 800 manuscripts per
year that are submitted to the journal. Finally, I
would like to take this opportunity to thank the

Journal of Pharmaceutical Sciences, Vol. 98, 1606–1607 (2009)

ß

2008 Wiley-Liss, Inc. and the American Pharmacists Association

1606

JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 98, NO. 5, MAY 2009

EAB members and the Associate Editors for their
dedication to

JPharmSci and for the time and

energy they have spent in the past 7.5 years
helping me as Editor to further strengthen this
journal and to better serve pharmaceutical
scientists worldwide.

Ronald T. Borchardt, Editor

Journal of Pharmaceutical Sciences

Published online in 00 Month 2008

Wiley InterScience (www.interscience.wiley.com)

DOI 10.1002/jps.21667

DOI 10.1002/jps

JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 98, NO. 5, MAY 2009

EDITORIAL

1607